Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that Glucophage powder for oral solution in sachet – metformin hydrochloride in 500mg, 850mg and 1000mg strengths – has received a positive opinion recommending approval for the first-line treatment of type 2 diabetes through a decentralized procedure with France as the reference member state.

Applications for marketing authorizations were filed in the 15 member states involved in the decentralized procedure. The launch of Glucophage powder for oral solution in sachet will be rolled out in the coming months following the delivery of the national marketing authorizations.

Richard Douge, executive vice president of marketing at Merck Serono, said: "The new formulation of Glucophage powder for oral solution in sachet allows for a rapid dissolution of the drug. It has been developed to offer patients a convenient alternative to tablets."